

evelyne Crapez

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6348719/evelyne-crapez-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

10
papers

787
citations

7
h-index

11
g-index

11
ext. papers

929
ext. citations

9.7
avg, IF

2.98
L-index

#	Paper	IF	Citations
10	Investigation of Molecular Features Involved in Clinical Responses and Survival in Advanced Endometrial Carcinoma Treated by Hormone Therapy. <i>Journal of Personalized Medicine</i> , 2022 , 12, 655	3.6	0
9	Clinicopathological Correlates of T Cell Infiltration in Triple-Negative Breast Cancer. <i>Cancers</i> , 2021 , 13,	6.6	3
8	Clinical Correlations of Programmed Cell Death Ligand 1 Status in Liquid and Standard Biopsies in Breast Cancer. <i>Clinical Chemistry</i> , 2020 , 66, 1093-1101	5.5	17
7	Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer. <i>Cancers</i> , 2020 , 12,	6.6	9
6	Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers. <i>British Journal of Cancer</i> , 2018 , 119, 76-79	8.7	37
5	Reproductive Decision-Making in MMR Mutation Carriers After Results Disclosure: Impact of Psychological Status in Childbearing Options. <i>Journal of Genetic Counseling</i> , 2016 , 25, 432-42	2.5	2
4	Circulating DNA as a Strong Multimarker Prognostic Tool for Metastatic Colorectal Cancer Patient Management Care. <i>Clinical Cancer Research</i> , 2016 , 22, 3067-77	12.9	110
3	Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. <i>Nature Medicine</i> , 2014 , 20, 430-5	50.5	474
2	Circulating Cell-Free DNA from Colorectal Cancer Patients May Reveal High KRAS or BRAF Mutation Load. <i>Translational Oncology</i> , 2013 , 6, 319-28	4.9	125
1	The non-crosslinking fixative RCL2 [®] -CS100 is compatible with both pathology diagnosis and molecular analyses. <i>Pathology and Oncology Research</i> , 2013 , 19, 41-53	2.6	10